> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Workshop on Measuring Gonadal Toxicity
- URL: https://www.fdaweb.com/workshop-on-measuring-gonadal-toxicity/
- Published: 2024-08-14T12:00:00.000Z
- Updated: 2026-09-14T14:38:17.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157575

FDA and the American Society of Clinical Oncology are announcing a [10/1 joint workshop](https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/measuring-toxicity-reproductive-organs-during-oncology-drug-development-fda-asco-virtual-workshop?ref=fdaweb.com) entitled “Measuring Toxicity in Reproductive Organs During Oncology Drug Development.” The workshop is intended to discuss measuring gonadal toxicity during oncology drug development. Specific topics include: 

- Highlighting patient voices and the importance of measuring gonadal toxicity during drug development to improve the quality of cancer care.
- Identifying nonclinical animal studies that support gonadal toxicity measurement
- Evaluating the use of surrogate endpoints and biomarkers for such measurements
- Exploring issues relevant to oncofertility, including fertility preservation options and pregnancy after cancer diagnosis and treatment